Capital Investment Advisory Services, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 190 filers reported holding CRISPR THERAPEUTICS AG in Q2 2019. The put-call ratio across all filers is 1.08 and the average weighting 0.6%.

Quarter-by-quarter ownership
Capital Investment Advisory Services, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$1,397,150
-16.6%
30,781
+3.1%
0.14%
-17.5%
Q2 2023$1,676,116
+26.2%
29,856
+1.6%
0.17%
+5.7%
Q1 2023$1,328,541
+19.9%
29,373
+7.7%
0.16%
+18.9%
Q4 2022$1,108,322
-42.2%
27,265
-7.0%
0.13%
-46.8%
Q3 2022$1,916,000
+11.7%
29,321
+3.9%
0.25%
+19.2%
Q2 2022$1,715,000
+1.2%
28,229
+4.6%
0.21%
+13.0%
Q1 2022$1,694,000
+9.6%
26,987
+32.3%
0.18%
+0.5%
Q4 2021$1,546,000
-37.5%
20,396
-7.6%
0.18%
-41.3%
Q3 2021$2,472,000
-32.5%
22,084
-2.3%
0.31%
-32.2%
Q2 2021$3,661,000
+44.8%
22,613
+9.0%
0.46%
+28.9%
Q1 2021$2,529,000
-1.3%
20,755
+24.1%
0.36%
-6.1%
Q4 2020$2,562,000
+38.9%
16,730
-24.2%
0.38%
+9.5%
Q3 2020$1,845,000
-6.4%
22,062
-17.8%
0.35%
-13.0%
Q2 2020$1,972,000
+90.2%
26,837
+9.8%
0.40%
+57.7%
Q1 2020$1,037,000
-27.6%
24,443
+4.0%
0.25%
-33.9%
Q4 2019$1,432,000
+48.2%
23,508
-0.3%
0.38%
+42.4%
Q3 2019$966,000
-19.4%
23,573
-2.9%
0.27%
-26.3%
Q2 2019$1,199,000
+46.9%
24,268
+6.2%
0.36%
+20.1%
Q1 2019$816,000
+13.0%
22,854
-9.6%
0.30%
-1.3%
Q4 2018$722,000
-3.7%
25,279
+49.6%
0.31%
-12.3%
Q3 2018$750,000
-29.0%
16,903
-5.9%
0.35%
-33.5%
Q2 2018$1,056,000
+63.2%
17,963
+26.9%
0.53%
+46.3%
Q1 2018$647,000
+167.4%
14,160
+37.5%
0.36%
+154.2%
Q4 2017$242,000
+25.4%
10,300
-4.6%
0.14%
+19.3%
Q3 2017$193,00010,8000.12%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q2 2019
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders